Search

An Explainable Machine Learning Approach Reveals Prognostic Significance of Right Ventricular Dysfunction in Nonischemic Cardiomyopathy Fahmy AS, Csecs I, Arafati A, Assana S, Yankama TT, Al-Otaibi T, Rodriguez J, Chen YY, Ngo LH, Manning WJ, Kwong RY, Nezafat R. Abstract Objectives: We implemented...

The Harvard Cardiovascular MR Center strives to make its research widely accesible through the sharing of open source codes and datasets whenever possible. Codes You can find codes on our lab's GitHub. To see all of our available project repositories, please click here. Data You can find datasets...

Accelerated Cardiac MR Imaging using a Resolution Enhancement Generative Adversarial Inline Neural Network Yoon S, Nakamori S, Amyar A, Assana S, Cirillo J, Morales M, Chow K, Bi X, Pierce P, Goddu B, Rodriguez J, Long N, Manning WJ, Nezafat R Abstract Background: Cardiac cine can benefit from deep...

Dear Colleagues, In this issue of eye Insights, we take a close look at posterior uveitis. Inside, you’ll find techniques and tips for evaluating and managing patients with this condition. Due to its many etiologies, posterior uveitis can be challenging to treat until the cause of the inflammation...

The most common symptoms of posterior uveitis are blurred vision and floaters, and the most common signs are chorioretinal infiltrates and vitreous cells. Posterior uveitis is diagnosed by slit lamp examination and indirect ophthalmoscopy. Imaging modalities, including fundus autofluorescence...

While gene therapy is not yet widely available for inherited retinal disorsers (IRDs), researchers are making exciting discoveries, and the future looks more promising than ever before. In this issue of eye Insights, we provide a look into current offerings in gene therapy, and a glimpse into the...

Inherited retinal disorders are rare, hereditary disorders caused by mutations in genes that encode proteins needed for normal retinal health and function. The first gene associated with retinitis pigmentosa was identified at Mass Eye and Ear in 1990, and since then, over 250 IRD-causing genes have...

The first gene-augmentation therapy for an IRD was approved by the U.S. Food and Drug Administration (FDA) in December 2017 after nearly two decades of development in preclinical models and clinical trials. The drug, known as Luxturna®, is for individuals with autosomal recessive retinal dystrophies...

Working Group Leads Richelle C. Charles, M.D. Associate Professor of Medicine, HMSAssociate Professor of Immunology & Infectious Diseases, HSPHAssociate Physician, Infectious Diseases, MGH Manish Sagar, M.D. Professor of Medicine, Boston University School of Medicine Kathryn E. Stephenson, M.D., M.P...

The effect of sodium oxybate (Xyrem ®) in a patient with laryngeal dystonia and voice tremor before (A) and after (B) drug intake (S imonyan K and Frucht SJ, Tremor Other Hyperkin Dis, 2013 ) Current treatment of laryngeal dystonia (LD) is limited to the temporary management of voice symptoms with...